Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 355

1.

A computational method for the identification of Dengue, Zika and Chikungunya virus species and genotypes.

Fonseca V, Libin PJK, Theys K, Faria NR, Nunes MRT, Restovic MI, Freire M, Giovanetti M, Cuypers L, Nowé A, Abecasis A, Deforche K, Santiago GA, Siqueira IC, San EJ, Machado KCB, Azevedo V, Filippis AMB, Cunha RVD, Pybus OG, Vandamme AM, Alcantara LCJ, de Oliveira T.

PLoS Negl Trop Dis. 2019 May 8;13(5):e0007231. doi: 10.1371/journal.pntd.0007231. eCollection 2019 May.

2.

Earlier Initiation of Antiretroviral Treatment Coincides With an Initial Control of the HIV-1 Sub-Subtype F1 Outbreak Among Men-Having-Sex-With-Men in Flanders, Belgium.

Vinken L, Fransen K, Cuypers L, Alexiev I, Balotta C, Debaisieux L, Seguin-Devaux C, García Ribas S, Gomes P, Incardona F, Kaiser R, Ruelle J, Sayan M, Paraschiv S, Paredes R, Peeters M, Sönnerborg A, Vancutsem E, Vandamme AM, Van den Wijngaert S, Van Ranst M, Verhofstede C, Stadler T, Lemey P, Van Laethem K.

Front Microbiol. 2019 Mar 26;10:613. doi: 10.3389/fmicb.2019.00613. eCollection 2019.

3.

Tracing the Impact of Public Health Interventions on HIV-1 Transmission in Portugal Using Molecular Epidemiology.

Vasylyeva TI, du Plessis L, Pineda-Peña AC, Kühnert D, Lemey P, Vandamme AM, Gomes P, Camacho RJ, Pybus OG, Abecasis AB, Faria NR.

J Infect Dis. 2019 Jun 19;220(2):233-243. doi: 10.1093/infdis/jiz085.

4.

Time to Harmonize Dengue Nomenclature and Classification.

Cuypers L, Libin PJK, Simmonds P, Nowé A, Muñoz-Jordán J, Alcantara LCJ, Vandamme AM, Santiago GA, Theys K.

Viruses. 2018 Oct 18;10(10). pii: E569. doi: 10.3390/v10100569.

5.

The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy.

Schultze A, Torti C, Cozzi-Lepri A, Vandamme AM, Zazzi M, Sambatakou H, De Luca A, Geretti AM, Sonnerborg A, Ruiz L, Monno L, Di Giambenedetto S, Gori A, Lapadula G; European Transmitted Drug Resistance collaboration (EU-TDR).

AIDS. 2019 Feb 1;33(2):315-326. doi: 10.1097/QAD.0000000000002046.

PMID:
30325769
6.

[Standardized Debriefing of Coercive Measures on Psychiatric Acute Wards: A Pilot Study].

Wullschleger A, Vandamme A, Ried J, Pluta M, Montag C, Mahler L.

Psychiatr Prax. 2019 Apr;46(3):128-134. doi: 10.1055/a-0651-6812. Epub 2018 Sep 25. German.

PMID:
30253421
7.

Predictors of non adherence to antiretroviral therapy at an urban HIV care and treatment center in Tanzania.

Sangeda RZ, Mosha F, Aboud S, Kamuhabwa A, Chalamilla G, Vercauteren J, Van Wijngaerden E, Lyamuya EF, Vandamme AM.

Drug Healthc Patient Saf. 2018 Aug 21;10:79-88. doi: 10.2147/DHPS.S143178. eCollection 2018.

8.

Ethical considerations in global HIV phylogenetic research.

Coltart CEM, Hoppe A, Parker M, Dawson L, Amon JJ, Simwinga M, Geller G, Henderson G, Laeyendecker O, Tucker JD, Eba P, Novitsky V, Vandamme AM, Seeley J, Dallabetta G, Harling G, Grabowski MK, Godfrey-Faussett P, Fraser C, Cohen MS, Pillay D; Ethics in HIV Phylogenetics Working Group.

Lancet HIV. 2018 Nov;5(11):e656-e666. doi: 10.1016/S2352-3018(18)30134-6. Epub 2018 Aug 30. Review.

PMID:
30174214
9.

[Contributions to reduce coercion in psychiatric care].

Wullschleger A, Mielau J, Mahler L, Vandamme A, Montag C.

Fortschr Neurol Psychiatr. 2018 Aug;86(8):500-508. doi: 10.1055/a-0604-2714. Epub 2018 Aug 20. Review. German.

PMID:
30125922
10.

Genome Detective: an automated system for virus identification from high-throughput sequencing data.

Vilsker M, Moosa Y, Nooij S, Fonseca V, Ghysens Y, Dumon K, Pauwels R, Alcantara LC, Vanden Eynden E, Vandamme AM, Deforche K, de Oliveira T.

Bioinformatics. 2019 Mar 1;35(5):871-873. doi: 10.1093/bioinformatics/bty695.

11.

Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis.

Cuypers L, Pérez AB, Chueca N, Aldamiz-Echevarría T, Alados JC, Martínez-Sapiña AM, Merino D, Pineda JA, Téllez F, Espinosa N, Salméron J, Rivero-Juarez A, Vivancos MJ, Hontañón V, Vandamme AM, García F.

PLoS One. 2018 Jul 25;13(7):e0201268. doi: 10.1371/journal.pone.0201268. eCollection 2018.

12.

Expert consensus statement on the science of HIV in the context of criminal law.

Barré-Sinoussi F, Abdool Karim SS, Albert J, Bekker LG, Beyrer C, Cahn P, Calmy A, Grinsztejn B, Grulich A, Kamarulzaman A, Kumarasamy N, Loutfy MR, El Filali KM, Mboup S, Montaner JS, Munderi P, Pokrovsky V, Vandamme AM, Young B, Godfrey-Faussett P.

J Int AIDS Soc. 2018 Jul;21(7):e25161. doi: 10.1002/jia2.25161.

13.

A genetic IFN/STAT1/FAS axis determines CD4 T stem cell memory levels and apoptosis in healthy controls and Adult T-cell Leukemia patients.

Khouri R, Silva-Santos G, Dierckx T, Menezes SM, Decanine D, Theys K, Silva AC, Farré L, Bittencourt A, Mangino M, Roederer M, Vandamme AM, Van Weyenbergh J.

Oncoimmunology. 2018 Feb 13;7(5):e1426423. doi: 10.1080/2162402X.2018.1426423. eCollection 2018.

14.

State of the Art in HIV Drug Resistance: Science and Technology Knowledge Gap.

Boucher CA, Bobkova MR, Geretti AM, Hung CC, Kaiser R, Marcelin AG, Streinu-Cercel A, van Wyk J, Dorr P, Vandamme AM.

AIDS Rev. 2018 Jan-Mar;20(1):27-42. Review.

PMID:
29628515
15.

State of the Art in HIV Drug Resistance: Surveillance and Regional Gaps.

Boucher CA, Bobkova MR, Hung CC, Kaiser R, Marcelin AG, Streinu-Cercel A, van Wyk J, Dorr P, Vandamme AM.

AIDS Rev. 2018 Jan-Mar;20(1):43-57. Review.

PMID:
29628514
16.

Transmission Networks of HCV Genotype 1a Enriched With Pre-existing Polymorphism Q80K Among HIV-Infected Patients With Acute Hepatitis C in Poland.

Parczewski M, Cielniak I, Kordek J, Aksak-Wąs B, Urbańska A, Leszczyszyn-Pynka M, Siwak E, Bociąga-Jasik M, Nowak A, Szymczak A, Zalewska M, Łojewski W, Vandamme AM, Lübke N, Cuypers L.

J Acquir Immune Defic Syndr. 2018 Apr 15;77(5):514-522. doi: 10.1097/QAI.0000000000001628. Erratum in: J Acquir Immune Defic Syndr. 2019 May 1;81(1):e27.

PMID:
29337848
17.

Phylogenetic analysis as a forensic tool in HIV transmission investigations.

Abecasis AB, Pingarilho M, Vandamme AM.

AIDS. 2018 Mar 13;32(5):543-554. doi: 10.1097/QAD.0000000000001728.

PMID:
29280759
18.

The impact of HIV-1 within-host evolution on transmission dynamics.

Theys K, Libin P, Pineda-Peña AC, Nowé A, Vandamme AM, Abecasis AB.

Curr Opin Virol. 2018 Feb;28:92-101. doi: 10.1016/j.coviro.2017.12.001. Epub 2017 Dec 21. Review.

19.

PhyloGeoTool: interactively exploring large phylogenies in an epidemiological context.

Libin P, Vanden Eynden E, Incardona F, Nowé A, Bezenchek A; EucoHIV Study Group, Sönnerborg A, Vandamme AM, Theys K, Baele G.

Bioinformatics. 2017 Dec 15;33(24):3993-3995. doi: 10.1093/bioinformatics/btx535.

20.

Zika genomics urgently need standardized and curated reference sequences.

Theys K, Libin P, Dallmeier K, Pineda-Peña AC, Vandamme AM, Cuypers L, Abecasis AB.

PLoS Pathog. 2017 Sep 7;13(9):e1006528. doi: 10.1371/journal.ppat.1006528. eCollection 2017 Sep. No abstract available.

21.

A18 Random amplification with next-generation sequencing to cover HIV and HCV full-length genomes.

Cuypers L, Conceição-Neto N, Dierickx T, Schrooten Y, Vrancken B, Van Wijngaerden E, Nevens F, Vandamme AM, Matthijnssens J, Van Laethem K.

Virus Evol. 2017 Mar 5;3(Suppl 1). pii: vew036.017. doi: 10.1093/ve/vew036.017. eCollection 2017 Mar. No abstract available.

22.

A36 Prevalence of HIV-1 subtypes in Slovenia with an emphasis on molecular and phylogenetic investigation of subtype A.

Mlakar J, Lunar MM, Abecasis AB, Vandamme AM, Tomažič J, Vovko TD, Pečavar B, Volčanšek G, Poljak M.

Virus Evol. 2017 Mar 5;3(Suppl 1). pii: vew036.035. doi: 10.1093/ve/vew036.035. eCollection 2017 Mar. No abstract available.

23.

A21 HIV-1 sub-subtype F1 outbreak among MSM in Belgium.

Vinken L, Fransen K, Pineda-Peña AC, Alexiev I, Balotta C, Debaisieux L, Devaux C, García Ribas S, Gomes P, Incardona F, Kaiser R, Ruelle J, Sayan M, Paraschiv S, Paredes R, Peeters M, Sonnerborg A, Vancutsem E, Van den Wijngaert S, Van Ranst M, Verhofstede C, Vandamme AM, Lemey P, Van Laethem K.

Virus Evol. 2017 Mar 5;3(Suppl 1). pii: vew036.020. doi: 10.1093/ve/vew036.020. eCollection 2017 Mar. No abstract available.

24.

Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.

Cuypers L, Libin P, Schrooten Y, Theys K, Di Maio VC, Cento V, Lunar MM, Nevens F, Poljak M, Ceccherini-Silberstein F, Nowé A, Van Laethem K, Vandamme AM.

Infect Genet Evol. 2017 Sep;53:15-23. doi: 10.1016/j.meegid.2017.05.007. Epub 2017 May 9.

PMID:
28499845
25.

Phylogenetic evidence for underreporting of male-to-male sex among human immunodeficiency virus-infected donors in the Netherlands and Flanders.

van de Laar TJ, Bezemer D, van Laethem K, Vandewalle G, de Smet A, van Wijngaerden E, Claas EC, van Sighem AI, Vandamme AM, Compernolle V, Zaaijer HL.

Transfusion. 2017 May;57(5):1235-1247. doi: 10.1111/trf.14097. Epub 2017 Apr 4.

PMID:
28375576
26.

Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy.

Cuypers L, Vrancken B, Fabeni L, Marascio N, Cento V, Di Maio VC, Aragri M, Pineda-Peña AC, Schrooten Y, Van Laethem K, Balog D, Focà A, Torti C, Nevens F, Perno CF, Vandamme AM, Ceccherini-Silberstein F.

BMC Evol Biol. 2017 Mar 7;17(1):70. doi: 10.1186/s12862-017-0913-3.

27.

A Fashi Lymphoproliferative Phenotype Reveals Non-Apoptotic Fas Signaling in HTLV-1-Associated Neuroinflammation.

Menezes SM, Leal FE, Dierckx T, Khouri R, Decanine D, Silva-Santos G, Schnitman SV, Kruschewsky R, López G, Alvarez C, Talledo M, Gotuzzo E, Nixon DF, Vercauteren J, Brassat D, Liblau R, Vandamme AM, Galvão-Castro B, Van Weyenbergh J.

Front Immunol. 2017 Feb 14;8:97. doi: 10.3389/fimmu.2017.00097. eCollection 2017.

28.

IFN-β induces greater antiproliferative and proapoptotic effects and increased p53 signaling compared with IFN-α in PBMCs of Adult T-cell Leukemia/Lymphoma patients.

Dierckx T, Khouri R, Menezes SM, Decanine D, Farre L, Bittencourt A, Vandamme AM, Van Weyenbergh J.

Blood Cancer J. 2017 Jan 27;7(1):e519. doi: 10.1038/bcj.2016.126. No abstract available.

29.

Large cluster outbreaks sustain the HIV epidemic among MSM in Quebec.

Brenner BG, Ibanescu RI, Hardy I, Stephens D, Otis J, Moodie E, Grossman Z, Vandamme AM, Roger M, Wainberg MA; the Montreal PHI, SPOT cohorts.

AIDS. 2017 Mar 13;31(5):707-717. doi: 10.1097/QAD.0000000000001383.

PMID:
28005684
30.

Male Circumcision and the Epidemic Emergence of HIV-2 in West Africa.

Sousa JD, Temudo MP, Hewlett BS, Camacho RJ, Müller V, Vandamme AM.

PLoS One. 2016 Dec 7;11(12):e0166805. doi: 10.1371/journal.pone.0166805. eCollection 2016.

31.

Family Aggregation of Human T-Lymphotropic Virus 1-Associated Diseases: A Systematic Review.

Alvarez C, Gotuzzo E, Vandamme AM, Verdonck K.

Front Microbiol. 2016 Oct 28;7:1674. eCollection 2016. Review.

32.

Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development.

Cuypers L, Li G, Neumann-Haefelin C, Piampongsant S, Libin P, Van Laethem K, Vandamme AM, Theys K.

Virus Evol. 2016 Sep 6;2(2):vew024. eCollection 2016 Jul.

33.

Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients.

Marascio N, Pavia G, Strazzulla A, Dierckx T, Cuypers L, Vrancken B, Barreca GS, Mirante T, Malanga D, Oliveira DM, Vandamme AM, Torti C, Liberto MC, Focà A; The SINERGIE-UMG Study Group.

Int J Mol Sci. 2016 Aug 27;17(9). pii: E1416. doi: 10.3390/ijms17091416.

34.

On the contribution of Angola to the initial spread of HIV-1.

Pineda-Peña AC, Varanda J, Sousa JD, Theys K, Bártolo I, Leitner T, Taveira N, Vandamme AM, Abecasis AB.

Infect Genet Evol. 2016 Dec;46:219-222. doi: 10.1016/j.meegid.2016.08.009. Epub 2016 Aug 10.

35.

Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.

Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme AM, Rockstroh JK.

Rev Med Virol. 2016 Nov;26(6):408-434. doi: 10.1002/rmv.1895. Epub 2016 Jul 12. Review.

PMID:
27401933
36.

HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial.

Cuypers L, Snoeck J, Kerremans L, Libin P, Crabbé R, Van Dooren S, Vuagniaux G, Vandamme AM.

Infect Genet Evol. 2016 Oct;44:169-181. doi: 10.1016/j.meegid.2016.06.050. Epub 2016 Jun 30.

PMID:
27374748
37.

The global spread of HIV-1 subtype B epidemic.

Magiorkinis G, Angelis K, Mamais I, Katzourakis A, Hatzakis A, Albert J, Lawyer G, Hamouda O, Struck D, Vercauteren J, Wensing A, Alexiev I, Åsjö B, Balotta C, Gomes P, Camacho RJ, Coughlan S, Griskevicius A, Grossman Z, Horban A, Kostrikis LG, Lepej SJ, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit JC, Sönnerborg A, Staneková D, Stanojevic M, Stylianou DC, Boucher CAB; SPREAD program, Nikolopoulos G, Vasylyeva T, Friedman SR, van de Vijver D, Angarano G, Chaix ML, de Luca A, Korn K, Loveday C, Soriano V, Yerly S, Zazzi M, Vandamme AM, Paraskevis D.

Infect Genet Evol. 2016 Dec;46:169-179. doi: 10.1016/j.meegid.2016.05.041. Epub 2016 Jun 2.

38.

Quantifying Next Generation Sequencing Sample Pre-Processing Bias in HIV-1 Complete Genome Sequencing.

Vrancken B, Trovão NS, Baele G, van Wijngaerden E, Vandamme AM, van Laethem K, Lemey P.

Viruses. 2016 Jan 7;8(1). pii: E12. doi: 10.3390/v8010012.

39.

Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.

Theys K, Van Laethem K, Gomes P, Baele G, Pineda-Peña AC, Vandamme AM, Camacho RJ, Abecasis AB.

AIDS Res Hum Retroviruses. 2016 May;32(5):427-33. doi: 10.1089/AID.2015.0095. Epub 2016 Jan 29.

40.

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ; SPREAD Program, Puchhammer-Stockl E, Sarcletti M, Schmied B, Geit M, Balluch G, Vandamme AM, Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Vandekerckhove LPR, Van den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Van Laethem K, Beshkov D, Alexiev I, Lepej SZ, Begovac J, Kostrikis L, Demetriades I, Kousiappa I, Demetriou V, Hezka J, Linka M, Maly M, Machala L, Nielsen C, Jørgensen LB, Gerstoft J, Mathiesen L, Pedersen C, Nielsen H, Laursen A, Kvinesdal B, Liitsola K, Ristola M, Suni J, Sutinen J, Descamps D, Assoumou L, Castor G, Grude M, Flandre P, Storto A, Hamouda O, Kücherer C, Berg T, Braun P, Poggensee G, Däumer M, Eberle J, Heiken H, Kaiser R, Knechten H, Korn K, Müller H, Neifer S, Schmidt B, Walter H, Gunsenheimer-Bartmeyer B, Harrer T, Paraskevis D, Hatzakis A, Zavitsanou A, Vassilakis A, Lazanas M, Chini M, Lioni A, Sakka V, Kourkounti S, Paparizos V, Antoniadou A, Papadopoulos A, Poulakou G, Katsarolis I, Protopapas K, Chryssos G, Drimis S, Gargalianos P, Xylomenos G, Lourida G, Psichogiou M, Daikos GL, Sipsas NV, Kontos A, Gamaletsou MN, Koratzanis G, Sambatakou H, Mariolis H, Skoutelis A, Papastamopoulos V, Georgiou O, Panagopoulos P, Maltezos E, Coughlan S, De Gascun C, Byrne C, Duffy M, Bergin C, Reidy D, Farrell G, Lambert J, O'Connor E, Rochford A, Low J, Coakely P, O'Dea S, Hall W, Mor O, Levi I, Chemtob D, Grossman Z, Zazzi M, de Luca A, Balotta C, Riva C, Mussini C, Caramma I, Capetti A, Colombo MC, Rossi C, Prati F, Tramuto F, Vitale F, Ciccozzi M, Angarano G, Rezza G, Kolupajeva T, Vasins O, Griskevicius A, Lipnickiene V, Schmit JC, Struck D, Sauvageot N, Hemmer R, Arendt V, Michaux C, Staub T, Sequin-Devaux C, Wensing AMJ, Boucher CAB, van de Vijver DAMC, van Kessel A, van Bentum PHM, Brinkman K, Connell BJ, van der Ende ME, Hoepelman IM, van Kasteren M, Kuipers M, Langebeek N, Richter C, Santegoets RMWJ, Schrijnders-Gudde L, Schuurman R, van de Ven BJM, Åsjö B, Kran AB, Ormaasen V, Aavitsland P, Horban A, Stanczak JJ, Stanczak GP, Firlag-Burkacka E, Wiercinska-Drapalo A, Jablonowska E, Maolepsza E, Leszczyszyn-Pynka M, Szata W, Camacho R, Palma C, Borges F, Paixão T, Duque V, Araújo F, Otelea D, Paraschiv S, Tudor AM, Cernat R, Chiriac C, Dumitrescu F, Prisecariu LJ, Stanojevic M, Jevtovic D, Salemovic D, Stanekova D, Habekova M, Chabadová Z, Drobkova T, Bukovinova P, Shunnar A, Truska P, Poljak M, Lunar M, Babic D, Tomazic J, Vidmar L, Vovko T, Karner P, Garcia F, Paredes R, Monge S, Moreno S, Del Amo J, Asensi V, Sirvent JL, de Mendoza C, Delgado R, Gutiérrez F, Berenguer J, Garcia-Bujalance S, Stella N, de Los Santos I, Blanco JR, Dalmau D, Rivero M, Segura F, Elías MJP, Alvarez M, Chueca N, Rodríguez-Martín C, Vidal C, Palomares JC, Viciana I, Viciana P, Cordoba J, Aguilera A, Domingo P, Galindo MJ, Miralles C, Del Pozo MA, Ribera E, Iribarren JA, Ruiz L, de la Torre J, Vidal F, Clotet B, Albert J, Heidarian A, Aperia-Peipke K, Axelsson M, Mild M, Karlsson A, Sönnerborg A, Thalme A, Navér L, Bratt G, Karlsson A, Blaxhult A, Gisslén M, Svennerholm B, Bergbrant I, Björkman P, Säll C, Mellgren Å, Lindholm A, Kuylenstierna N, Montelius R, Azimi F, Johansson B, Carlsson M, Johansson E, Ljungberg B, Ekvall H, Strand A, Mäkitalo S, Öberg S, Holmblad P, Höfer M, Holmberg H, Josefson P, Ryding U.

Clin Infect Dis. 2016 Mar 1;62(5):655-663. doi: 10.1093/cid/civ963. Epub 2015 Nov 29.

41.

Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance.

Cuypers L, Li G, Libin P, Piampongsant S, Vandamme AM, Theys K.

Viruses. 2015 Sep 16;7(9):5018-39. doi: 10.3390/v7092857.

42.

Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals.

Winand R, Theys K, Eusébio M, Aerts J, Camacho RJ, Gomes P, Suchard MA, Vandamme AM, Abecasis AB; Portuguese HIV-1 Resistance Study Group.

AIDS. 2015 Sep 24;29(15):2045-52. doi: 10.1097/QAD.0000000000000811. Erratum in: AIDS. 2016 Feb 20;30(4):679.

43.

Disentangling the impact of within-host evolution and transmission dynamics on the tempo of HIV-1 evolution.

Vrancken B, Baele G, Vandamme AM, van Laethem K, Suchard MA, Lemey P.

AIDS. 2015 Jul 31;29(12):1549-56. doi: 10.1097/QAD.0000000000000731.

44.

CRF19_cpx is an Evolutionary fit HIV-1 Variant Strongly Associated With Rapid Progression to AIDS in Cuba.

Kouri V, Khouri R, Alemán Y, Abrahantes Y, Vercauteren J, Pineda-Peña AC, Theys K, Megens S, Moutschen M, Pfeifer N, Van Weyenbergh J, Pérez AB, Pérez J, Pérez L, Van Laethem K, Vandamme AM.

EBioMedicine. 2015 Jan 28;2(3):244-54. doi: 10.1016/j.ebiom.2015.01.015. eCollection 2015 Mar.

45.

HIV-1 genotypic drug resistance testing: digging deep, reaching wide?

Van Laethem K, Theys K, Vandamme AM.

Curr Opin Virol. 2015 Oct;14:16-23. doi: 10.1016/j.coviro.2015.06.001. Epub 2015 Jun 24. Review.

PMID:
26114581
46.

Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis.

Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Kee PN, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HM, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW.

PLoS Med. 2015 Jun 1;12(6):e1001845. doi: 10.1371/journal.pmed.1001845. eCollection 2015 Jun. No abstract available.

47.

Bridging epidemiology with population genetics in a low incidence MSM-driven HIV-1 subtype B epidemic in Central Europe.

Lunar MM, Vandamme AM, Tomažič J, Karner P, Vovko TD, Pečavar B, Volčanšek G, Poljak M, Abecasis AB.

BMC Infect Dis. 2015 Feb 15;15:65. doi: 10.1186/s12879-015-0802-6.

48.

Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.

Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, Rinke de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Ng KP, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HM, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW.

PLoS Med. 2015 Apr 7;12(4):e1001810. doi: 10.1371/journal.pmed.1001810. eCollection 2015 Apr. Erratum in: PLoS Med. 2015 Jun;12(6):e1001845.

49.

An integrated map of HIV genome-wide variation from a population perspective.

Li G, Piampongsant S, Faria NR, Voet A, Pineda-Peña AC, Khouri R, Lemey P, Vandamme AM, Theys K.

Retrovirology. 2015 Feb 15;12:18. doi: 10.1186/s12977-015-0148-6.

50.

Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.

Theys K, Camacho RJ, Gomes P, Vandamme AM, Rhee SY; Portuguese HIV-1 Resistance Study Group.

Clin Microbiol Infect. 2015 Jun;21(6):607.e1-8. doi: 10.1016/j.cmi.2015.02.011. Epub 2015 Feb 19.

Supplemental Content

Loading ...
Support Center